A multicenter randomized study comparing the dose dense, G-CSF [filgrastim]-supported sequential administration of FE75C [fluorouracil + epirubicin + cyclophosphamide] followed by docetaxel versus paclitaxel as adjuvant chemotherapy in women with axillary lymph node positive breast cancer

Trial Profile

A multicenter randomized study comparing the dose dense, G-CSF [filgrastim]-supported sequential administration of FE75C [fluorouracil + epirubicin + cyclophosphamide] followed by docetaxel versus paclitaxel as adjuvant chemotherapy in women with axillary lymph node positive breast cancer

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Dec 2012

At a glance

  • Drugs Docetaxel (Primary) ; Paclitaxel (Primary) ; Cyclophosphamide; Epirubicin; Fluorouracil
  • Indications Early breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Dec 2012 Results presented at the 35th Annual San Antonio Breast Cancer Symposium.
    • 22 Nov 2007 Status changed from recruiting to completed.
    • 08 Mar 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top